WO2007146349A3 - Cgrp receptor antagonists - Google Patents

Cgrp receptor antagonists Download PDF

Info

Publication number
WO2007146349A3
WO2007146349A3 PCT/US2007/013896 US2007013896W WO2007146349A3 WO 2007146349 A3 WO2007146349 A3 WO 2007146349A3 US 2007013896 W US2007013896 W US 2007013896W WO 2007146349 A3 WO2007146349 A3 WO 2007146349A3
Authority
WO
WIPO (PCT)
Prior art keywords
cgrp receptor
receptor antagonists
conditions
pharmaceutical compositions
relates
Prior art date
Application number
PCT/US2007/013896
Other languages
French (fr)
Other versions
WO2007146349A2 (en
Inventor
Corey Gutierrez
Andreas Termin
Sara Hadida-Ruah
Pramod Joshi
Daniele Bergeron
Sanghee Yoo
Hayley Binch
Jon Come
Suganthi Nanthakumar
Jingrong Cao
Original Assignee
Vertex Pharma
Corey Gutierrez
Andreas Termin
Sara Hadida-Ruah
Pramod Joshi
Daniele Bergeron
Sanghee Yoo
Hayley Binch
Jon Come
Suganthi Nanthakumar
Jingrong Cao
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharma, Corey Gutierrez, Andreas Termin, Sara Hadida-Ruah, Pramod Joshi, Daniele Bergeron, Sanghee Yoo, Hayley Binch, Jon Come, Suganthi Nanthakumar, Jingrong Cao filed Critical Vertex Pharma
Priority to JP2009515476A priority Critical patent/JP5382799B2/en
Priority to AU2007258294A priority patent/AU2007258294A1/en
Priority to EP07796082A priority patent/EP2027106A2/en
Priority to CA002655085A priority patent/CA2655085A1/en
Priority to NZ574097A priority patent/NZ574097A/en
Priority to MX2008015906A priority patent/MX2008015906A/en
Publication of WO2007146349A2 publication Critical patent/WO2007146349A2/en
Publication of WO2007146349A3 publication Critical patent/WO2007146349A3/en
Priority to IL195807A priority patent/IL195807A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/08—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D277/12—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/14—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/10—Spiro-condensed systems

Abstract

The present invention relates to CGRP receptor antagonists, pharmaceutical compositions thereof, and methods therewith for treating CGRP receptor-mediated diseases and conditions. The present invention relates to CGRP receptor antagonists of formula 1, wherein: X is S, SO, or SO2; pharmaceutical compositions thereof, and methods therewith for treating CGRP receptor-mediated diseases and conditions.
PCT/US2007/013896 2006-06-13 2007-06-13 Cgrp receptor antagonists WO2007146349A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
JP2009515476A JP5382799B2 (en) 2006-06-13 2007-06-13 CGRP receptor antagonist
AU2007258294A AU2007258294A1 (en) 2006-06-13 2007-06-13 CGRP receptor antagonists
EP07796082A EP2027106A2 (en) 2006-06-13 2007-06-13 Cgrp receptor antagonists
CA002655085A CA2655085A1 (en) 2006-06-13 2007-06-13 Cgrp receptor antagonists
NZ574097A NZ574097A (en) 2006-06-13 2007-06-13 Cgrp receptor antagonists
MX2008015906A MX2008015906A (en) 2006-06-13 2007-06-13 Cgrp receptor antagonists.
IL195807A IL195807A0 (en) 2006-06-13 2008-12-09 Cgrp receptor antagonists

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81317806P 2006-06-13 2006-06-13
US60/813,178 2006-06-13

Publications (2)

Publication Number Publication Date
WO2007146349A2 WO2007146349A2 (en) 2007-12-21
WO2007146349A3 true WO2007146349A3 (en) 2008-09-25

Family

ID=38832524

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/013896 WO2007146349A2 (en) 2006-06-13 2007-06-13 Cgrp receptor antagonists

Country Status (12)

Country Link
EP (1) EP2027106A2 (en)
JP (1) JP5382799B2 (en)
CN (1) CN101501009A (en)
AR (1) AR061362A1 (en)
AU (1) AU2007258294A1 (en)
CA (1) CA2655085A1 (en)
IL (1) IL195807A0 (en)
MX (1) MX2008015906A (en)
NZ (1) NZ574097A (en)
TW (1) TW200813019A (en)
WO (1) WO2007146349A2 (en)
ZA (1) ZA200810791B (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7834000B2 (en) * 2006-06-13 2010-11-16 Vertex Pharmaceuticals Incorporated CGRP receptor antagonists
JP5451646B2 (en) * 2008-02-27 2014-03-26 ヴァイティー ファーマシューティカルズ，インコーポレイテッド Inhibitors of 11β-hydroxysteroid dehydrogenase type 1
JP5923375B2 (en) * 2012-04-24 2016-05-24 花王株式会社 CGRP response promoter
US9198898B2 (en) 2013-06-24 2015-12-01 Tigercat Pharma, Inc. Use of NK-1 receptor antagonists in pruritus
US8906951B1 (en) 2013-06-24 2014-12-09 Tigercat Pharma, Inc. Use of NK-1 receptor antagonists in pruritus
JO3669B1 (en) * 2015-01-06 2020-08-27 Ferring Bv CGRP Antagonist Peptides
WO2019112024A1 (en) * 2017-12-08 2019-06-13 キッセイ薬品工業株式会社 Pyrrolidine compound
EP3740477A1 (en) 2018-01-19 2020-11-25 Idorsia Pharmaceuticals Ltd C5a receptor modulators
US20210121541A1 (en) * 2019-07-05 2021-04-29 Allergan Pharmaceuticals International Limited CGRP Antagonists and Clostridial Derivatives for the Treatment of Neuropsychiatric and Neurological Disorders
WO2021005493A1 (en) * 2019-07-05 2021-01-14 Allergan Pharmaceuticals International Limited Cgrp antagonists and botulinum toxins for the treatment of inflammatory and neurologic disorders

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003104236A1 (en) * 2002-06-01 2003-12-18 Bristol-Myers Squibb Company Calcitonin gene related peptide receptor antagonists
WO2004017965A1 (en) * 2002-08-23 2004-03-04 Ionix Pharmaceuticals Limited 1,3-thiazolin-4-ones as therapeutic compounds in the treatment of pain
WO2004092166A2 (en) * 2003-04-15 2004-10-28 Merck & Co., Inc. Cgrp receptor antagonists

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4705912B2 (en) * 2003-06-26 2011-06-22 メルク・シャープ・エンド・ドーム・コーポレイション Benzodiazepine CGRP receptor antagonist

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003104236A1 (en) * 2002-06-01 2003-12-18 Bristol-Myers Squibb Company Calcitonin gene related peptide receptor antagonists
WO2004017965A1 (en) * 2002-08-23 2004-03-04 Ionix Pharmaceuticals Limited 1,3-thiazolin-4-ones as therapeutic compounds in the treatment of pain
WO2004092166A2 (en) * 2003-04-15 2004-10-28 Merck & Co., Inc. Cgrp receptor antagonists

Also Published As

Publication number Publication date
IL195807A0 (en) 2009-09-01
AU2007258294A1 (en) 2007-12-21
JP5382799B2 (en) 2014-01-08
AR061362A1 (en) 2008-08-20
EP2027106A2 (en) 2009-02-25
JP2009539997A (en) 2009-11-19
NZ574097A (en) 2012-01-12
ZA200810791B (en) 2010-03-31
TW200813019A (en) 2008-03-16
MX2008015906A (en) 2009-03-06
CA2655085A1 (en) 2007-12-21
WO2007146349A2 (en) 2007-12-21
CN101501009A (en) 2009-08-05

Similar Documents

Publication Publication Date Title
WO2007146349A3 (en) Cgrp receptor antagonists
WO2009020470A3 (en) Cgrp receptor antagonists
WO2006044504A8 (en) Cgrp receptor antagonists
WO2006099268A3 (en) Cgrp receptor antagonists
WO2006047196A3 (en) Cgrp receptor antagonists
WO2007079214A3 (en) Prokineticin 2 receptor antagonists
ATE469895T1 (en) CGRP RECEPTOR ANTAGONISTS
WO2006004741A3 (en) 3-aminocyclopentanecarboxamides as modulators of chemokine receptors
WO2006041830A3 (en) Cgrp receptor antagonists
WO2006029153A3 (en) Monocyclic anilide spirolactam cgrp receptor antagonists
WO2006004684A8 (en) 3-aminocyclopentanecarboxamides as modulators of chemokine receptors
MX2008012400A (en) Azolopyrimidines as inhibitors of cannabinoid 1 activity.
WO2005072308A3 (en) Cgrp receptor antagonists
WO2004091514A3 (en) Cgrp receptor antagonists
WO2005115392A8 (en) 3-(4-heteroarylcyclohexylamino) cyclopentanecarboxamides as modulators of chemokine receptors
TW200505903A (en) CGRP receptor antagonists
MX2009003981A (en) Calcium receptor modulating agents.
WO2007079163A3 (en) Prokineticin 1 receptor antagonists
WO2007120980A3 (en) 2,4-pyrimidinediamine compounds for treating or preventing autoimmune diseases
WO2007016087A3 (en) Heterocyclic benzodiazepine cgrp receptor antagonists
WO2007061677A3 (en) Spirolactam aryl cgrp receptor antagonists
WO2007072201A3 (en) 3-aminocyclopentanecarboxamides as modulators of chemokine receptors
TW200720260A (en) Prokineticin 1 receptor antagonists
WO2006044449A3 (en) Cgrp receptor antagonists
WO2008112159A3 (en) Monocyclic anilide spirolactam cgrp receptor antagonists

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200780029737.4

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07796082

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 195807

Country of ref document: IL

ENP Entry into the national phase

Ref document number: 2655085

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: MX/A/2008/015906

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2009515476

Country of ref document: JP

Ref document number: 2007796082

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2007258294

Country of ref document: AU

Ref document number: 574097

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 116/KOLNP/2009

Country of ref document: IN

NENP Non-entry into the national phase

Ref country code: RU

ENP Entry into the national phase

Ref document number: 2007258294

Country of ref document: AU

Date of ref document: 20070613

Kind code of ref document: A